https://webantonio.onrender.com/ weekly 1 https://webantonio.onrender.com/sobre-mi monthly 0.75 https://webantonio.onrender.com/casos-clinicos monthly 0.75 https://webantonio.onrender.com/noticias monthly 0.75 https://webantonio.onrender.com/editoriales monthly 0.75 https://webantonio.onrender.com/investigacion monthly 0.75 https://webantonio.onrender.com/reflexiones monthly 0.75 https://webantonio.onrender.com/orientacion-oncologica-remota monthly 0.75 https://webantonio.onrender.com/historias monthly 0.75 https://webantonio.onrender.com/galeria monthly 0.75 https://webantonio.onrender.com/editoriales/editorial-cancer-de-pulmon-y-quimioterapia 2026-04-23T16:09:46.533Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-belzutifan-lenvatinib-cancer-renal-avanzado-inmunoterapia 2026-09-28T22:34:25.722Z monthly 0.7 https://webantonio.onrender.com/casos-clinicos/cancer-renal-metastasico-con-respuesta-completa-prolongada-a-nivolumab-tras-dos- 2026-09-28T20:07:11.760Z monthly 0.85 https://webantonio.onrender.com/noticias/trastuzumab-rezetecan-mejora-supervivencia-libre-progresion-cancer 2026-09-28T19:56:35.696Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-amplia-primera-linea-aprobacion-acelerada-sevabertinib-cancer-pulmon 2026-09-24T08:57:05.049Z monthly 0.7 https://webantonio.onrender.com/noticias/panel-asesor-fda-respalda-galleri-pero-deja-dividida-evidencia-eficacia 2026-09-24T03:00:12.786Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-lirafugratinib-colangiocarcinoma-fgfr2-positivo-previamente 2026-09-23T20:58:56.296Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-pide-nuevo-ensayo-supervivencia-antes-aceptar-solicitud-tovecimig 2026-09-23T14:59:59.407Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-bravnetsa-nueva-opcion-lutecio-177-tumores-neuroendocrinos 2026-09-23T02:59:02.228Z monthly 0.7 https://webantonio.onrender.com/noticias/ivonescimab-quimioterapia-supera-durvalumab-quimioterapia-supervivencia 2026-09-22T21:00:04.858Z monthly 0.7 https://webantonio.onrender.com/noticias/ivonescimab-mejora-supervivencia-global-frente-pembrolizumab 2026-09-22T14:56:25.685Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-somete-revision-expertos-test-galleri-alta-especificidad-pero 2026-09-22T02:58:53.210Z monthly 0.7 https://webantonio.onrender.com/noticias/atg-022-entra-fase-iii-cancer-gastrico-cldn18-2-positivo 2026-09-21T20:58:50.647Z monthly 0.7 https://webantonio.onrender.com/noticias/vitamina-c-no-frena-expansion-clonal-pero-evita-encuentra-senal 2026-09-21T14:59:07.278Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-concede-breakthrough-therapy-daraxonrasib-quimioterapia 2026-09-21T08:57:38.204Z monthly 0.7 https://webantonio.onrender.com/noticias/car-t-dirigido-gpc3-logra-regresion-completa-hepatoblastoma-metastasico 2026-09-21T02:58:28.282Z monthly 0.7 https://webantonio.onrender.com/noticias/chmp-recomienda-ensartinib-cancer-pulmon-alk-positivo-consolida 2026-09-20T20:59:46.839Z monthly 0.7 https://webantonio.onrender.com/noticias/tambotatug-pelitecan-prolonga-supervivencia-cancer-pulmon-microcitico 2026-09-20T09:00:21.730Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-pixclara-primer-pet-18f-fet-autorizado-ee-uu 2026-09-20T02:58:18.817Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-reduce-22-24-6-8-horas-monitorizacion-inicial-tarlatamab 2026-09-19T20:59:24.620Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-ameluz-fototerapia-luz-roja-carcinoma-basocelular 2026-09-19T14:59:47.907Z monthly 0.7 https://webantonio.onrender.com/noticias/chmp-recomienda-teclistamab-monoterapia-primera-recaida-mieloma-multiple 2026-09-19T08:58:15.565Z monthly 0.7 https://webantonio.onrender.com/noticias/chmp-recomienda-pembrolizumab-enfortumab-vedotina-antes-despues-cirugia 2026-09-19T02:58:49.550Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-imlunestrant-abemaciclib-cancer-mama-er-her2-mutacion-esr1 2026-09-18T20:55:53.384Z monthly 0.7 https://webantonio.onrender.com/noticias/chmp-recomienda-relacorilant-nab-paclitaxel-cancer-ovario-resistente 2026-09-18T14:59:57.294Z monthly 0.7 https://webantonio.onrender.com/noticias/acalabrutinib-prolonga-supervivencia-libre-progresion-72-5-meses-linfoma 2026-09-18T08:55:23.989Z monthly 0.7 https://webantonio.onrender.com/noticias/nice-recomienda-enhertu-cancer-mama-her2-low-avanzado-inglaterra 2026-09-18T02:57:02.801Z monthly 0.7 https://webantonio.onrender.com/noticias/camizestrant-palbociclib-no-alcanza-objetivo-primario-pfs-primera-linea 2026-09-17T20:58:04.492Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-incorpora-mediana-49-7-meses-duracion-respuesta-taletrectinib-cpnm 2026-09-17T14:59:59.057Z monthly 0.7 https://webantonio.onrender.com/noticias/mosunetuzumab-lenalidomida-mejora-supervivencia-libre-progresion 2026-09-17T08:56:17.611Z monthly 0.7 https://webantonio.onrender.com/noticias/zidesamtinib-alcanza-94-respuestas-primera-linea-cpnm-ros1-positivo 2026-09-17T02:55:44.006Z monthly 0.7 https://webantonio.onrender.com/noticias/gotistobart-casi-duplica-supervivencia-global-frente-docetaxel-cpnm 2026-09-16T20:58:43.893Z monthly 0.7 https://webantonio.onrender.com/noticias/amigo-1-alcanza-objetivo-supervivencia-libre-progresion-18-meses 2026-09-16T18:28:33.795Z monthly 0.7 https://webantonio.onrender.com/noticias/daraxonrasib-muestra-actividad-cancer-pulmon-ras-mutado-lleva-inhibicion 2026-09-11T02:59:10.059Z monthly 0.7 https://webantonio.onrender.com/noticias/micvotabart-pelidotin-muestra-respuestas-rapidas-fase-i-cancer-cabeza 2026-09-10T08:59:50.097Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-amplia-aprobacion-acelerada-sevabertinib-primera-linea-cpnm 2026-09-10T02:56:37.033Z monthly 0.7 https://webantonio.onrender.com/noticias/dabogratinib-muestra-respuesta-79-fase-ii-cancer-vesical-no-musculo 2026-09-09T20:57:35.090Z monthly 0.7 https://webantonio.onrender.com/noticias/darovasertib-crizotinib-entra-fase-iii-prevenir-recaida-metastasica 2026-09-09T14:56:45.415Z monthly 0.7 https://webantonio.onrender.com/noticias/arlocabtagene-autoleucel-alcanza-objetivos-clave-fase-ii-quintessential 2026-09-08T20:56:00.712Z monthly 0.7 https://webantonio.onrender.com/noticias/tarlatamab-durvalumab-mejora-significativamente-supervivencia-global 2026-09-08T14:56:50.281Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-retira-aprobacion-acelerada-adagrasib-cetuximab-cancer-colorrectal 2026-09-08T02:59:37.844Z monthly 0.7 https://webantonio.onrender.com/noticias/nmpa-acepta-solicitud-hs-20093-adc-anti-b7-h3-ya 2026-09-07T20:59:06.712Z monthly 0.7 https://webantonio.onrender.com/noticias/sunvozertinib-avanza-posible-primera-linea-cpnm-egfr-exon-20-fda 2026-09-07T14:55:18.144Z monthly 0.7 https://webantonio.onrender.com/noticias/atezolizumab-anadido-sbrt-no-mejora-supervivencia-cancer-pulmon-temprano 2026-09-07T08:59:32.975Z monthly 0.7 https://webantonio.onrender.com/noticias/mt027-recibe-fast-track-fda-glioblastoma-recurrente-lleva-fase-ii 2026-09-07T02:56:15.615Z monthly 0.7 https://webantonio.onrender.com/noticias/inmunoterapia-dual-antes-cirugia-activa-microambiente-tumoral 2026-09-06T14:59:16.512Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-ropeginterferon-alfa-2b-trombocitemia-esencial-2 2026-09-06T08:56:32.895Z monthly 0.7 https://webantonio.onrender.com/noticias/ivonescimab-quimioterapia-reduce-48-riesgo-progresion-resistencia-egfr-2 2026-09-06T02:58:23.286Z monthly 0.7 https://webantonio.onrender.com/noticias/ace723-obtiene-autorizacion-ind-fda-lleva-fase-i-adc-doble 2026-09-05T20:55:54.205Z monthly 0.7 https://webantonio.onrender.com/noticias/alectinib-mantiene-calidad-vida-perfil-seguridad-manejable-cirugia 2026-09-05T02:54:17.820Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-camizestrant-guiado-ctdna-cancer-mama-avanzado-mutacion-esr1 2026-09-04T20:57:01.126Z monthly 0.7 https://webantonio.onrender.com/noticias/seguimiento-guiado-ctdna-duplica-recaidas-cancer-colorrectal-tratadas 2026-09-04T14:59:11.059Z monthly 0.7 https://webantonio.onrender.com/noticias/radioterapia-hipofraccionada-mantiene-control-oncologico-menos-sesiones 2026-09-04T09:01:23.197Z monthly 0.7 https://webantonio.onrender.com/noticias/ivonescimab-demuestra-beneficio-supervivencia-global-frente 2026-09-04T02:57:22.657Z monthly 0.7 https://webantonio.onrender.com/noticias/azacitidina-venetoclax-prolonga-doble-supervivencia-libre-eventos-frente 2026-09-03T20:57:22.036Z monthly 0.7 https://webantonio.onrender.com/noticias/etentamig-reduce-60-riesgo-progresion-muerte-mieloma-multiple-recaida 2026-09-03T14:58:48.292Z monthly 0.7 https://webantonio.onrender.com/noticias/daraxonrasib-muestra-actividad-antitumoral-cancer-pulmon-no-microcitico 2026-09-03T08:55:20.953Z monthly 0.7 https://webantonio.onrender.com/noticias/jbs-003-recibe-designacion-breakthrough-therapy-fda-guiar-desescalada 2026-09-03T02:54:31.756Z monthly 0.7 https://webantonio.onrender.com/casos-clinicos/respuesta-inesperada-en-cancer-de-recto-metastasico-tras-una-combinacion-terapeu 2026-09-04T15:11:11.108Z monthly 0.85 https://webantonio.onrender.com/noticias/fda-aprueba-daraxonrasib-primera-terapia-dirigida-ras-adenocarcinoma 2026-09-02T20:57:34.846Z monthly 0.7 https://webantonio.onrender.com/noticias/selinexor-ruxolitinib-llega-fda-resultados-fase-iii-mielofibrosis-busca 2026-09-02T14:58:41.789Z monthly 0.7 https://webantonio.onrender.com/noticias/bipass-completa-reclutamiento-fase-iii-busca-redefinir-cuando-puede 2026-09-02T08:54:43.826Z monthly 0.7 https://webantonio.onrender.com/noticias/comision-europea-aprueba-trastuzumab-deruxtecan-pertuzumab 2026-09-02T02:58:04.933Z monthly 0.7 https://webantonio.onrender.com/noticias/atezolizumab-no-mejora-significativamente-supervivencia-libre-eventos 2026-09-01T22:25:44.010Z monthly 0.7 https://webantonio.onrender.com/noticias/osimertinib-savolitinib-mejora-supervivencia-libre-progresion 2026-09-01T22:12:08.264Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-ropeginterferon-alfa-2b-trombocitemia-esencial 2026-09-01T22:12:08.763Z monthly 0.7 https://webantonio.onrender.com/noticias/biontech-detiene-fase-ii-vacuna-mrna-personalizada-cancer-colorrectal 2026-09-01T21:45:39.022Z monthly 0.7 https://webantonio.onrender.com/noticias/zanidatamab-tislelizumab-quimioterapia-mejora-supervivencia-cancer 2026-09-01T22:12:09.095Z monthly 0.7 https://webantonio.onrender.com/noticias/varseta-m-recibe-fast-track-fda-abre-nueva-via-atacar 2026-09-01T21:45:39.665Z monthly 0.7 https://webantonio.onrender.com/noticias/sys6090-recibe-fast-track-fda-cancer-colorrectal-metastasico-mss-pmmr 2026-09-01T21:45:39.987Z monthly 0.7 https://webantonio.onrender.com/noticias/cirugia-conversion-atezolizumab-bevacizumab-prolonga-control 2026-09-01T22:12:09.423Z monthly 0.7 https://webantonio.onrender.com/noticias/inmunoterapia-neoadyuvante-botensilimab-balstilimab-profundiza 2026-09-01T21:45:40.627Z monthly 0.7 https://webantonio.onrender.com/noticias/gedatolisib-busca-ampliar-alcance-cancer-mama-pik3ca-mutado-ventaja-pfs 2026-09-01T21:45:40.950Z monthly 0.7 https://webantonio.onrender.com/noticias/mayor-analisis-clinico-chordoma-avanzado-fija-nuevo-punto-referencia-orr 2026-09-01T21:45:41.273Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-daraxonrasib-primera-terapia-dirigida-ras-cancer-pancreas 2026-09-01T21:45:41.596Z monthly 0.7 https://webantonio.onrender.com/noticias/biomarcador-sanguineo-podria-decidir-pacientes-melanoma-braf-necesitan 2026-09-01T21:45:41.916Z monthly 0.7 https://webantonio.onrender.com/noticias/177lu-betabart-avanza-70-mci-fase-i-iia-explora-b7 2026-09-01T21:45:42.237Z monthly 0.7 https://webantonio.onrender.com/noticias/ivonescimab-quimioterapia-mejora-supervivencia-global-frente-durvalumab 2026-09-01T22:12:09.754Z monthly 0.7 https://webantonio.onrender.com/noticias/datopotamab-deruxtecan-rilvegostomig-entran-fase-iii-reducir-riesgo 2026-09-01T21:45:42.879Z monthly 0.7 https://webantonio.onrender.com/noticias/teclistamab-adelanta-inmunoterapia-biespecifica-recaida-temprana-mieloma 2026-09-01T21:45:43.200Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-concede-fast-track-gi-101a-cancer-urotelial-avanzado-inmunoterapia 2026-09-01T21:45:43.523Z monthly 0.7 https://webantonio.onrender.com/noticias/programa-fusion-tfe3-revela-carcinoma-renal-translocacion 2026-09-01T21:45:43.844Z monthly 0.7 https://webantonio.onrender.com/noticias/radiacion-incidental-timo-asocia-metastasis-peor-supervivencia-cancer 2026-09-01T22:12:10.088Z monthly 0.7 https://webantonio.onrender.com/noticias/belzutifan-lenvatinib-prolonga-supervivencia-libre-progresion 2026-09-01T22:12:10.416Z monthly 0.7 https://webantonio.onrender.com/noticias/iberdomide-inaugura-nueva-clase-degradadores-proteinas-aprobacion 2026-09-01T21:45:44.811Z monthly 0.7 https://webantonio.onrender.com/noticias/nym096-lleva-radioligandoterapia-dirigida-caix-cancer-renal-metastasico 2026-09-01T21:45:45.133Z monthly 0.7 https://webantonio.onrender.com/noticias/dostarlimab-recibe-revision-prioritaria-fda-cancer-recto-dmmr-msi-h 2026-09-01T21:45:45.456Z monthly 0.7 https://webantonio.onrender.com/noticias/177lu-psma-617-lleva-medicina-radioligada-primera-linea-cancer-prostata 2026-09-01T21:45:45.777Z monthly 0.7 https://webantonio.onrender.com/noticias/biomarcador-inteligencia-artificial-podria-personalizar-quimioterapia 2026-09-01T21:45:46.100Z monthly 0.7 https://webantonio.onrender.com/noticias/reserva-ovarica-medida-amh-podria-identificar-mujeres-jovenes-cancer 2026-09-01T21:45:46.421Z monthly 0.7 https://webantonio.onrender.com/noticias/rezatapopt-muestra-actividad-cancer-ovario-avanzado-mutacion-tp53-y220c 2026-09-01T21:45:46.741Z monthly 0.7 https://webantonio.onrender.com/noticias/durvalumab-bcg-retrasa-recaidas-alto-riesgo-reduce-necesidad-cistectomia 2026-09-01T22:12:10.745Z monthly 0.7 https://webantonio.onrender.com/noticias/programa-digital-medicina-integrativa-asocia-mayor-supervivencia 2026-09-01T21:45:47.384Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-aprueba-zanidatamab-primera-linea-cancer-gastroesofagico-her2 2026-09-01T21:45:47.706Z monthly 0.7 https://webantonio.onrender.com/noticias/terapia-mrna-personalizada-supera-primera-vez-fase-iii-melanoma 2026-09-01T21:45:48.028Z monthly 0.7 https://webantonio.onrender.com/noticias/asp2138-entra-fase-iii-cancer-gastrico-cldn18-2-positivo-combinar 2026-09-01T21:45:48.349Z monthly 0.7 https://webantonio.onrender.com/noticias/ivonescimab-quimioterapia-reduce-48-riesgo-progresion-resistencia-egfr 2026-09-01T22:12:11.072Z monthly 0.7 https://webantonio.onrender.com/noticias/terapia-neoadyuvante-total-intensificada-mejora-supervivencia-libre 2026-09-01T21:45:48.990Z monthly 0.7 https://webantonio.onrender.com/noticias/ensayo-optima-muestra-muchas-pacientes-cancer-mama-er-her2-pueden 2026-09-01T21:45:49.311Z monthly 0.7 https://webantonio.onrender.com/noticias/darovasertib-crizotinib-reduce-58-riesgo-progresion-melanoma-uveal 2026-09-01T22:12:11.400Z monthly 0.7 https://webantonio.onrender.com/noticias/glp-1-asocia-mayor-supervivencia-quimioterapia-cancer-colorrectal 2026-09-01T21:45:49.954Z monthly 0.7 https://webantonio.onrender.com/noticias/combinacion-bloquea-cxcr4-abre-via-inmunologica-cancer-pancreas 2026-09-01T21:45:50.275Z monthly 0.7 https://webantonio.onrender.com/noticias/astrazeneca-detiene-fase-iii-volrustomig-considerar-improbable-beneficio 2026-09-01T21:45:50.598Z monthly 0.7 https://webantonio.onrender.com/noticias/numero-senales-alarma-permite-afinar-riesgo-cancer-pacientes-quistes 2026-09-01T21:45:50.972Z monthly 0.7 https://webantonio.onrender.com/noticias/cisplatino-semanal-mantiene-control-locorregional-menos-toxicidad-cancer 2026-09-01T21:45:51.292Z monthly 0.7 https://webantonio.onrender.com/noticias/star-trec-quimiorradioterapia-permite-preservar-recto-cuatro-cada-cinco 2026-09-01T21:45:51.615Z monthly 0.7 https://webantonio.onrender.com/noticias/comision-europea-aprueba-sacituzumab-govitecan-pembrolizumab 2026-09-01T22:12:11.729Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-concede-fast-track-eras-0015-nuevo-enfoque-pan-ras 2026-09-01T21:45:52.257Z monthly 0.7 https://webantonio.onrender.com/noticias/comision-europea-aprueba-teclistamab-daratumumab-nueva-opcion 2026-09-01T22:12:12.055Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-concede-revision-prioritaria-dostarlimab-cancer-recto-dmmr-msi-h 2026-09-01T21:45:52.899Z monthly 0.7 https://webantonio.onrender.com/noticias/japon-aprueba-sevabertinib-terapia-dirigida-cancer-pulmon-no-microcitico 2026-09-01T22:12:12.381Z monthly 0.7 https://webantonio.onrender.com/noticias/avelumab-metotrexato-logra-control-duradero-tumores-trofoblasticos 2026-09-01T22:12:12.707Z monthly 0.7 https://webantonio.onrender.com/noticias/ak157d1-entra-fase-i-nuevo-adc-dirigido-b7-h3-tumores 2026-09-01T22:12:13.037Z monthly 0.7 https://webantonio.onrender.com/noticias/abbvie-anticipa-nuevos-datos-inmunoterapia-adc-cancer-pulmon-wclc-2026 2026-09-01T21:45:54.183Z monthly 0.7 https://webantonio.onrender.com/noticias/opamtistomig-entra-revision-prioritaria-china-carcinoma-neuroendocrino 2026-09-01T21:45:54.504Z monthly 0.7 https://webantonio.onrender.com/noticias/vacuna-personalizada-arnm-mejora-control-melanoma-ensayo-fase-iii 2026-09-01T21:45:54.825Z monthly 0.7 https://webantonio.onrender.com/noticias/brii-5395-entra-evaluacion-clinica-vacuna-terapeutica-arnm 2026-09-01T22:12:13.364Z monthly 0.7 https://webantonio.onrender.com/noticias/china-autoriza-inicio-ensayos-clinicos-hbm7004-anticuerpo-biespecifico 2026-09-01T21:45:55.468Z monthly 0.7 https://webantonio.onrender.com/noticias/adn-tumoral-circulante-identifica-senales-beneficio-nivolumab-cancer 2026-09-01T21:45:55.790Z monthly 0.7 https://webantonio.onrender.com/noticias/biontech-presentara-wclc-nuevos-datos-inmunoterapia-combinada-cancer 2026-09-01T21:45:56.111Z monthly 0.7 https://webantonio.onrender.com/noticias/alk201-ivonescimab-entran-fase-ii-cancer-pulmon-escamoso-fgfr2b-positivo 2026-09-01T21:45:56.433Z monthly 0.7 https://webantonio.onrender.com/noticias/car-t-dirigido-psma-muestra-actividad-clinica-cancer-prostata-resistente 2026-09-01T21:45:56.755Z monthly 0.7 https://webantonio.onrender.com/noticias/estrategia-quimioterapia-muestra-actividad-duradera-cancer-mama 2026-09-01T21:45:57.078Z monthly 0.7 https://webantonio.onrender.com/noticias/car-t-dirigido-b7-h3-muestra-senales-eficacia-glioblastoma-recurrente 2026-09-01T21:45:57.399Z monthly 0.7 https://webantonio.onrender.com/noticias/ablacion-campos-electricos-pulsados-activa-respuesta-inmune-cancer 2026-09-01T21:45:57.721Z monthly 0.7 https://webantonio.onrender.com/noticias/mesutoclax-avanza-fase-iii-frente-venetoclax-leucemia-mieloide-aguda 2026-09-01T21:45:58.044Z monthly 0.7 https://webantonio.onrender.com/noticias/evx-05-vacuna-terapeutica-off-shelf-disenada-ia-avanza-ensayos 2026-09-01T21:45:58.365Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-concede-fast-track-safusidenib-gliomas-mutacion-idh1 2026-09-01T21:45:58.685Z monthly 0.7 https://webantonio.onrender.com/noticias/akeso-abre-ensayo-fase-iii-cadonilimab-cancer-gastrico-her2-negativo 2026-09-01T21:45:59.006Z monthly 0.7 https://webantonio.onrender.com/noticias/enfortumab-vedotina-pembrolizumab-supera-cisplatino-cancer-vejiga 2026-09-01T22:12:13.691Z monthly 0.7 https://webantonio.onrender.com/noticias/pelareorep-avanza-posible-estudio-pivotal-cancer-colorrectal-ras-mutado 2026-09-01T21:45:59.647Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-concede-via-fast-track-bh-30643-cancer-pulmon-resistencia 2026-09-01T21:45:59.968Z monthly 0.7 https://webantonio.onrender.com/noticias/sunvozertinib-supera-quimioterapia-primera-linea-cancer-pulmon-egfr 2026-09-01T22:12:14.018Z monthly 0.7 https://webantonio.onrender.com/noticias/car-t-dirigido-cldn18-2-logra-control-prolongado-metastasis-peritoneales 2026-09-01T21:46:00.611Z monthly 0.7 https://webantonio.onrender.com/noticias/fda-frena-aprobacion-nuevo-radiofarmaco-tumores-neuroendocrinos 2026-09-01T21:46:00.933Z monthly 0.7 https://webantonio.onrender.com/noticias/radioterapia-dirigida-hueso-no-mejora-control-metastasis-oseas-cancer 2026-09-01T21:46:01.258Z monthly 0.7 https://webantonio.onrender.com/noticias/vacuna-personalizada-arnm-reduce-recaida-melanoma-ensayo-fase-iii 2026-09-01T21:46:01.580Z monthly 0.7 https://webantonio.onrender.com/noticias/ensartinib-reduce-forma-marcada-recaida-cancer-pulmon-alk-positivo 2026-09-01T21:46:01.904Z monthly 0.7 https://webantonio.onrender.com/noticias/iberdomide-nueva-clase-terapeutica-mieloma-multiple-recaida 2026-09-01T21:46:02.228Z monthly 0.7 https://webantonio.onrender.com/noticias/abemaciclib-abre-nueva-via-dirigida-liposarcoma-desdiferenciado-avanzado 2026-09-01T21:46:02.549Z monthly 0.7 https://webantonio.onrender.com/noticias/dos-resultados-fase-iii-refuerzan-terapia-dirigida-cancer-pulmon-egfr 2026-09-01T21:46:02.869Z monthly 0.7 https://webantonio.onrender.com/noticias/nueva-inmunoterapia-viral-melanoma-resistente-anti-pd-1 2026-09-01T21:46:03.191Z monthly 0.7 https://webantonio.onrender.com/noticias/selpercatinib-amplia-oncologia-precision-indicacion-agnostica-tumor 2026-09-01T21:46:03.514Z monthly 0.7 https://webantonio.onrender.com/noticias/daraxonrasib-nuevo-capitulo-cancer-pancreas-metastasico 2026-09-01T21:46:03.835Z monthly 0.7 https://webantonio.onrender.com/casos-clinicos/una-masa-en-la-amigdala-que-no-era-una-infeccion-tumor-smarca4-deficiente-metast 2026-08-18T15:16:38.453Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/carcinoma-mucinoso-primario-de-apendice-con-celulas-en-anillo-de-sello-y-carcino 2026-08-12T19:58:59.454Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/cancer-de-prostata-metastasico-resistente-a-castracion-cuando-el-perfil-molecula 2026-08-12T19:11:04.204Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/cancer-de-ovario-avanzado-y-viscum-album-resultados-positivos-y-el-desafio-de-in 2026-08-12T17:03:07.251Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/carcinoma-de-merkel-del-nodulo-cutaneo-al-tratamiento-neoadyuvante-con-inmunoter 2026-08-12T16:48:17.985Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/tratamiento-de-conversion-y-reseccion-de-metastasis-hepaticas-en-cancer-de-colon 2026-08-11T20:40:02.119Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/respuesta-patologica-completa-tras-tratamiento-neoadyuvante-en-cancer-de-mama-he 2026-08-11T20:36:15.667Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/melanoma-maligno-primario-de-mucosa-oral-e-hiperprogresion-inducida-por-inmunote 2026-08-11T18:33:26.678Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/sacituzumab-govitecan-como-tratamiento-de-primera-linea-2 2026-07-31T20:08:08.574Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/cuando-un-dolor-abdominal-persistente-revelo-un-cancer-de-colon 2026-07-30T18:34:17.731Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/cancer-y-ovarios-poliquisticos-relacion-y-cuidados-8 2026-07-30T23:10:36.023Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/cancer-pulmon-no-microcitico-estadio-iv-decision-terapeutica 2026-07-23T15:30:39.479Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/cancer-mama-her2-escalamiento-terapeutico 2026-07-23T15:30:39.496Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/linfoma-difuso-celulas-grandes-b-diagnostico-consolidacion 2026-07-23T15:30:39.506Z monthly 0.85 https://webantonio.onrender.com/casos-clinicos/cancer-renal 2026-06-01T14:55:43.457Z monthly 0.85 https://webantonio.onrender.com/reflexiones/el-tiempo-de-la-escucha-en-oncologia 2026-07-23T15:30:39.519Z monthly 0.7 https://webantonio.onrender.com/investigacion/como-leer-estudios-y-guias-oncologicas 2026-07-23T15:30:39.561Z monthly 0.7 https://webantonio.onrender.com/casos-clinicos/cancer-gastrico-con-metastasis-oseas-e-ninfiltracion-leptomeningea 2026-07-31T17:33:06.998Z monthly 0.85 https://webantonio.onrender.com/noticias/recomendaciones-esmo-2024-cancer-colorrectal 2026-07-23T15:30:39.529Z monthly 0.7 https://webantonio.onrender.com/noticias/terapia-dirigida-cancer-pulmon-actualizacion-evidencia 2026-07-23T15:30:39.542Z monthly 0.7 https://webantonio.onrender.com/noticias/inmunoterapia-perioperatoria-melanoma-resecable 2026-07-23T15:30:39.552Z monthly 0.7